Sierra Oncology, Inc.
SRRADelisted Jul 1, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001290149
Sierra Oncology, Inc. was delisted on Jul 1, 2022; its insiders filed their last Form 4 on Jul 1, 2022; 109 institutions reported holding it in 13F filings for Q2 2022, worth $1.23B in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 109
- Q2 2022, +35 vs. previous quarter
- 13F value
- $1.23B
- Reported value at the end of Q2 2022
- Superinvestors holding
- 0
- At the end of Q2 2022
Superinvestors holding SRRA, Q2 2022
No superinvestor reported holding SRRA at the end of Q2 2022.
Latest insider trades
Open-market purchases and sales by Sierra Oncology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 7, 2022 (view filing) | Apr 5-6 | 2 days | Turner William D.Chief Reg & Tech Ops Officer | SSale | −6.45K | $37.25 | −$240.1K | −100.0%0 after | 2 lots |
| Apr 4, 2022 (view filing) | Apr 4 | Same day | Thomson Mary ChristinaGeneral Counsel, CCO & Sec'y | SSale | −2.00K | $35.14 | −$70.3K | −100.0%0 after | |
| Mar 22, 2022 (view filing) | Mar 18 | 4 days | Turner William D.Chief Reg & Tech Ops Officer | SSale | −100 | $37.05 | −$3.71K | −100.0%0 after | |
| Mar 17, 2022 (view filing) | Mar 17 | Same day | Turner William D.Chief Reg & Tech Ops Officer | SSale | −3.45K | $37.06 | −$128.0K | −100.0%0 after | |
| Mar 4, 2022 (view filing) | Mar 4 | Same day | Thomson Mary ChristinaGeneral Counsel, CCO & Sec'y | SSale | −2.00K | $30.60 | −$61.2K | −100.0%0 after | |
| Feb 8, 2022 (view filing) | Feb 7 | 1 day | Turner William D.Chief Reg & Tech Ops Officer | SSale | −10.0K | $32.32 | −$323.2K | −100.0%0 after | |
| Feb 4, 2022 (view filing) | Feb 4 | Same day | Thomson Mary ChristinaGeneral Counsel, CCO & Sec'y | SSale | −2.00K | $29.78 | −$59.6K | −100.0%0 after | |
| Feb 2, 2022 (view filing)9:25 PM ET | Feb 2 | Same day | Enright Patrick G and 5 others10% Owner | PPurchase | +175.0K | $27.00 | +$4.72M | New position175.0K after | Duplicate filing |
| Feb 2, 2022 (view filing) | Feb 2 | Same day | Richardson JoshuaDirector, 10% Owner | PPurchase | +175.0K | $27.00 | +$4.72M | New position175.0K after | |
| Feb 1, 2022 (view filing) | Jan 31 | 1 day | Sinclair AndrewDirector | PPurchaseCommon Stock, $0.001 par value | +150.0K | $27.00 | +$4.05M | +12.9%1.31M after | Duplicate filing |
Top 10 13F holders, Q2 2022
The largest institutional positions in Sierra Oncology, Inc. at the end of Q2 2022; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 3,329,509 | $183.1M | 18.38% | −20.0% | Reduced |
| OrbiMed Advisors LLC | 1,964,770 | $108.0M | 2.10% | 00.0% | Unchanged |
| Versor Investments LP | 1,579,751 | $86.9M | 3.33% | +1,579,751 | New |
| Abingworth LLP | 1,314,127 | $72.3M | 23.14% | +1150.0% | Added |
| Rock Springs Capital Management LP | 1,174,786 | $64.6M | 1.88% | 00.0% | Unchanged |
| BlackRock Inc. | 1,169,751 | $64.3M | 0.00% | +721,321+160.9% | Added |
| Magnetar Financial LLC | 1,106,649 | $60.9M | 0.70% | +1,106,649 | New |
| TIG Advisors, LLC | 891,117 | $49.0M | 2.06% | +891,117 | New |
| Frazier Life Sciences Management, L.P. | 870,636 | $47.9M | 4.52% | −1,471,562−62.8% | Reduced |
| Paradigm Biocapital Advisors LP | 801,314 | $44.1M | 8.79% | +30,000+3.9% | Added |